Benzinga | Jul 6, 2021 06:33AM EDT

MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For The Treatment Of Ophthalmic Disease

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of ophthalmic disease.